Neuphoria Therapeutics Inc. (NEUP) SEC filings

NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026Score 5/30

$2.58−0.13 (-4.80%)

Close on Nov 12, 2026Market cap $77.56KP/E –Yield –

SEC filings

40 of Neuphoria Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Oct 23, 2026	Oct 23, 2026	SEC EDGAR
Annual report	10-K	Jun 30, 2026	Sep 18, 2026	SEC EDGAR
Proxy statement	DEF 14A	Nov 2, 2026	Sep 18, 2026	SEC EDGAR
Current report	8-K	Jul 20, 2026	Jul 24, 2026	SEC EDGAR
Current report	8-K	May 21, 2026	May 26, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 15, 2026	SEC EDGAR
Quarterly report	10-Q	Dec 31, 2025	Feb 17, 2026	SEC EDGAR
Current report	8-K	Dec 31, 2025	Jan 8, 2026	SEC EDGAR
Current report	8-K	Dec 18, 2025	Dec 18, 2025	SEC EDGAR
Current report	8-K	Dec 12, 2025	Dec 17, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 14, 2025	SEC EDGAR
Proxy statement	DEF 14A	Dec 9, 2025	Oct 30, 2025	SEC EDGAR
Current report	8-K	Oct 27, 2025	Oct 27, 2025	SEC EDGAR
Current report	8-K	Oct 20, 2025	Oct 20, 2025	SEC EDGAR
Annual report	10-K	Jun 30, 2025	Sep 29, 2025	SEC EDGAR
Current report	8-K	Sep 10, 2025	Sep 16, 2025	SEC EDGAR
Current report	8-K	Jul 18, 2025	Jul 18, 2025	SEC EDGAR
Current report	8-K	May 20, 2025	May 20, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 20, 2025	SEC EDGAR
Quarterly report	10-Q	Dec 31, 2024	Feb 14, 2025	SEC EDGAR
Current report	8-K	Jan 10, 2025	Jan 14, 2025	SEC EDGAR
Current report	8-K	Dec 23, 2024	Dec 23, 2024	SEC EDGAR
Current report	8-K	Dec 16, 2024	Dec 16, 2024	SEC EDGAR
Current report	8-K	Dec 11, 2024	Dec 12, 2024	SEC EDGAR
Current report	8-K	Nov 18, 2024	Nov 21, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 14, 2024	SEC EDGAR
Proxy statement	DEF 14A	Dec 11, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 8, 2024	Nov 8, 2024	SEC EDGAR
Current report	8-K	Oct 9, 2024	Oct 10, 2024	SEC EDGAR
Current report	8-K	Oct 1, 2024	Oct 2, 2024	SEC EDGAR
Annual report	10-K	Jun 30, 2024	Sep 30, 2024	SEC EDGAR
Current report	8-K	Jul 11, 2024	Jul 16, 2024	SEC EDGAR
Current report	6-K	Jun 3, 2024	Jun 3, 2024	SEC EDGAR
Current report	6-K	Mar 15, 2024	Mar 15, 2024	SEC EDGAR
Annual report, amended	20-F/A	Jun 30, 2023	Jan 17, 2024	SEC EDGAR
Current report	6-K	Jan 4, 2024	Jan 4, 2024	SEC EDGAR
Current report	6-K	Nov 30, 2023	Nov 30, 2023	SEC EDGAR
Current report	6-K	Nov 28, 2023	Nov 28, 2023	SEC EDGAR
Current report	6-K	Nov 3, 2023	Nov 3, 2023	SEC EDGAR
Annual report	20-F	Jun 30, 2023	Oct 18, 2023	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Neuphoria Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2160 reverse split on Feb 14, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NEUP.

Compare: NEUP vs IGC · NEUP vs KRSA · NEUP vs DNTH · NEUP vs OVID · NEUP vs ATXI

Revenue growth-92.5% · median -46.7%

Operating margin-1401.1% · median -2843.5%

Net margin-1145.7% · median -1836.7%

Company	Revenue	Growth
OVID	$1.45M	-78.0%
NEUP	$1.17M	-92.5%
IGC	$1.12M	-15.4%
KRSA	–	–
DNTH	–	–
ATXI	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 7
Held by institutions: 36.8%
Auditor: Wolf & Company P.C.
SEC CIK: 1191070

Advertisement
300 × 250

See a number that looks wrong?